SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
female hand hold human brain on yellow background.
Alzheimer’s disease
Roche’s Next-Gen Alzheimer’s Antibody Clears or Reduces Amyloid Plaques in Seven Months
In a Phase Ib/IIa trial, 91% of patients receiving the highest dose of trontinemab were amyloid negative after seven months of treatment, representing what B. Riley Securities called a “paradigm shift” to first-generation FDA-approved antibodies.
July 28, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Business negotiation and cooperation vector concept. Symbol of a deal, handshake, success. Minimal design eps10 illustration.
Deals
Boehringer Links with Irish Drug Delivery Start-Up Re-Vana in $1B+ Eye Deal
The German giant is looking to develop new drugs for undisclosed eye diseases using Re-Vana’s extended-release injectable platform to supply drugs to the eye for months at a time.
July 28, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Collage of a man hand giving a one hundred dollar bill to a woman hand on a yellow circle on a beige scratched background
Deals
GSK Bets Up To $12B for Multi-Program Cancer Pact With Hengrui
The star of GSK’s Hengrui partnership is the COPD candidate HRS-9821, which will complement the pharma’s respiratory pipeline that’s anchored by the anti-asthma drug Nucala.
July 28, 2025
 · 
2 min read
 · 
Tristan Manalac
Government
American Medical Association Urges RFK Jr. to Maintain Preventive Task Force
Health Secretary Robert F. Kennedy Jr. wants to remove all members of the USPSTF for being too “woke,” according to reporting by the Wall Street Journal. An HHS spokesperson, however, says no final decision has been made about the panel.
July 28, 2025
 · 
2 min read
 · 
Tristan Manalac
A concept of unfair social prejudice. The miniature men and a magnifying glass.
Duchenne muscular dystrophy
Sarepta Denies Latest Patient Death is Elevidys-Linked as FDA Launches Probe
Brazilian authorities said the death was unlikely to have been caused by Elevidys and was instead more in line with severe infection exacerbated by immunosuppression.
July 28, 2025
 · 
2 min read
 · 
Tristan Manalac
Business and financial crisis vector concept with businessman falling down the hole. Symbol of market crash, recession, risk, bankruptcy and loss. Eps10 illustration.
Schizophrenia
Atai-Partnered Schizophrenia Drug Flunks Mid-Stage Trial
Despite the failure of its Recognify-partnered inidascamine, Jefferies analysts do not expect a definitively negative stock impact on atai, given the company’s promising psychedelic pipeline.
July 28, 2025
 · 
2 min read
 · 
Tristan Manalac
Art and Paintings around and inside human's brain profile - Collage
Alzheimer’s disease
As Alzheimer’s Space Heats Up, Biopharma Leans In to Holistic Treatment
Acknowledging the limits of disease-modifying drugs like Leqembi and Kisunla, companies like Bristol Myers Squibb, Acadia, Otsuka and Lundbeck are renewing a decades-old search for symptomatic treatments, including in high-profile drugs like Cobenfy.
July 28, 2025
 · 
7 min read
 · 
Heather McKenzie
Mental health and problems with memory. Hands unraveling tangled red threads on head silhouette representing brain. Modern art collage.
Alzheimer’s disease
5 Alzheimer’s Readouts To Watch
These five upcoming data drops could usher in more effective and convenient therapies for Alzheimer’s disease and open up novel pathways of action to treat the memory-robbing illness.
July 28, 2025
 · 
8 min read
 · 
Tristan Manalac
Confused businessman stands in front of different arrows . The concept of hard choices.
Regulatory
Drug Pricing Just One Point of Confusion Over New FDA Vouchers
The Commissioner’s National Priority Vouchers aim to offer accelerated pathways to drugs that meet certain criteria, perhaps including a low price-tag. But the policy is vaguely defined and was announced without public input, going against the FDA’s own published practices, experts say.
July 28, 2025
 · 
4 min read
 · 
Dan Samorodnitsky
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS